Navigation Links
Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18

Note 2: The first analysis in the table (i.e., HPV 16- or 18-related CIN 2/3, AIS or worse) was the primary endpoint of the vaccine development plan. Note 3: FUTURE I refers to Protocol 013; FUTURE II refers to Protocol 015. ---------------------------------------------------------------------- GARDASIL was efficacious against HPV disease caused by each of the 4 vaccine HPV types. In a pre-defined analysis, the efficacy of GARDASIL against HPV 16/18-related disease was 100% (95% CI: 87.9%, 100.0%) for CIN 3 or AIS and 100% (95% CI: 55.5%, 100.0%) for VIN 2/3 or VaIN 2/3. The efficacy of GARDASIL against HPV 6-, 11-, 16-, and 18-related VIN 1 or VaIN 1 was 100% (95% CI: 75.8%, 100.0%). These analyses were conducted in the PPE population that consisted of individuals who received all 3 vaccinations within 1 year of enrollment, did not have major deviations from the study protocol, and were naive (PCR negative and seronegative) to the relevant HPV type(s) (Types 6, 11, 16, and 18) prior to dose 1 and through 1 month Postdose 3 (Month 7). Efficacy in Subjects with Current or Prior Infection GARDASIL is a prophylactic vaccine. There was no clear evidence of protection from disease caused by HPV types for which subjects were PCR positive and/or seropositive at baseline. Individuals who were already infected with 1 or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV types. General Population Impact The general population of young American women includes women who are HPV-naive (PCR negative and seronegative) and women who are HPV-non-naive (PCR positive and/or seropositive), some of whom have HPV-related disease. The clinical trials population approximated the general population of American women with respect to prevalence of HPV infection and disease at enrollment. Analyses were conducted to evaluate the overall impact of GARDASIL w
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine) Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
(Date:2/26/2015)... 2015 RnRMarketResearch.com adds Corneal ... report to its store. This report p provides ... The report "Corneal Ulcers - Pipeline Review, H2 ... for Corneal Ulcers. Corneal Ulcers are primarily result ... viral infections & fungal infections. The symptoms of ...
(Date:2/26/2015)... NORTH CHICAGO, Ill. , Feb. 26, 2015 ... announced that 15 abstracts of studies in its ... for presentation during the 67 th American ... Washington, D.C. , from April 18-25. The ... FDA-approved product, DUOPA, in addition to investigational treatments ...
(Date:2/26/2015)... 2015  IRIDEX Corporation (NASDAQ: IRIX ) today ... year 2014 financial results after the market closes on ... the Company will host a conference call with the investment ... Thursday, March 5, 2015 to discuss the results of ... may access the live conference call via telephone by dialing ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... VIVUS, Inc. (NASDAQ: VVUS ) today announced that ... the peer-reviewed journal of The Obesity Society. The EQUIP study ... 1,267 severely obese (BMI >/= 35 kg/m 2 ) patients across ... of 14.4% of initial body weight among those who completed the ...
... Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS ... financial results for the fiscal 2012 first quarter ended September 30, ... Management has scheduled a conference call for 4:30 p.m. ... Thursday, November 10, 2011 at 8:30 AM AEDT) , to ...
Cached Medicine Technology:Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6Unilife Corporation to Announce Financial Results For Fiscal 2012 First Quarter on Wednesday, November 9, 2011 2Unilife Corporation to Announce Financial Results For Fiscal 2012 First Quarter on Wednesday, November 9, 2011 3
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:2/28/2015)... Santa Cruz, california (PRWEB) February 28, 2015 ... an ever growing number of practicing physicians as a way ... experience, training or education regarding Cannabis as medicine. Since the ... have been very few resources available to licensed physicians ... treatment to a patient. Dr. Deborah Malka in Santa ...
(Date:2/28/2015)... Calgary, AB (PRWEB) February 28, 2015 ... and is now a distributor of the machine. The ... part of their license, like a franchise model. The ... people prevent and reverse heart disease. To buy ... Heart Fit Clinic can help individuals through this process ...
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, ... pleased to announce the development of Q-Suite 5.9. Building ... of Q-Suite, this new version will include enhancements to ... features to the leading edge call center software. General ... add features to enhance security and protection. Administrators will ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... Company) (NYSE: BDX ), a global medical technology company,announced today that ... 2008 Annual Credit Suisse Healthcare Conference ... pm ET, Lazard Capital Markets 5th Annual ... 10:55 a.m. ET, A live webcast of BD,s ...
... (human papillomavirus) vaccines and the validation of a simple oral ... studies by a Johns Hopkins Kimmel Cancer Center investigator. , ... identify HPV infection as the cause of certain oral cancers ... risk factor for these cancers, reports her latest work in ...
... Taking Medications for Blood Pressure, Cholesterol, ... Asthma, ADD/ADHD, Depression and Diabetes, ST. LOUIS, Nov. 3 ... type 2 diabetes medications between 2002 and,2005, with girls between ... One likely cause: Obesity, which is closely associated with type,2 ...
... Declared, ACTON, Mass., Nov. 3 Psychemedics Corporation,(Nasdaq: ... for the,period ended September 30, 2008. The Company also ... shareholders of record as of,December 3, 2008 to be ... 49th consecutive quarterly dividend., The Company,s third quarter ...
... Robbins & Myers, Inc.,(NYSE: RBN ) announced ... Conference on November 11, 2008. The Company will be ... and Christopher,M. Hix, Vice President and Chief Financial Officer., ... CST, at,the Four Seasons Hotel in Chicago, Illinois. It ...
... Leading Cause of Death in U.S., SWANTON, Vt., ... Month, to help raise awareness about Chronic,Obstructive Pulmonary Disease ... will be making downloadable,tips available to COPD patients on ... November newsletter and blogs to raising awareness,about this 4th ...
Cached Medicine News:Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 2Health News:Research indicates need for effective HPV vaccine for women and men and a simple HPV screening test 3Health News:Tweens and Teens Double Use of Diabetes Drugs 2Health News:Tweens and Teens Double Use of Diabetes Drugs 3Health News:Tweens and Teens Double Use of Diabetes Drugs 4Health News:Psychemedics Corporation Announces Third Quarter Results 2Health News:Psychemedics Corporation Announces Third Quarter Results 3Health News:Psychemedics Corporation Announces Third Quarter Results 4Health News:Psychemedics Corporation Announces Third Quarter Results 5Health News:AllerAir Dedicates November to COPD Awareness Month 2
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
These are simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in healthcare facilities....
Pre-Saturated Sponge Sticks...
... be a valuable tool in standardizing protocols ... necessary for a procedure are supplied in ... of care are easier to be established ... of use, allowing the clinician to progress ...
Medicine Products: